The DOI matches its Crossref record.
HDAC Inhibitors-New Generation of Target Specific Treatment
Abstract
Histone Deacetylases (HDACs) enzymes are critical in regulating gene expression and transcription. They also play a fundamental role in regulating cellular activities such as cell proliferation, survival and differentiation. Inhibition of HDACs has generated many fascinating results including a new strategy in human cancer therapy. HDAC Inhibitors (HDACIs) like SAHA, TSA are emerging as new promising drugs for various anti-inflammatory and CNS-disorders. This review, along with chemical classification, emphasizes on the therapeutic potential of various HDACIs against different diseases. Keywords: Histone Deacetylase, HDAC inhibitor, chemistry, therapeutic applications, Enzyme Histone acetyltransferases, HAT, Class III HDACs, sirtuins, nu-clear receptor co-repressor, N-coR, Silencing Mediator, Thyroid receptors, SMRT, HDAC enzyme, aliphatic chain, Large hydrophobic region, Hydroxamic acids, trichostatin, TSA, suberoylanilide hydroxamic acid, SAHA, oxamflatin, Cyclic tetrapeptides, Benzamides, MS-27-275, Short-chain fatty acids, butyrates, Streptomyces hygro-scopicus, NVP-LAQ824, LAQ824, PDX 101, LDH589, Depsipeptide FK228, Chromobacterium violaceum, Apicidin, tubacin, Vorinostat, suberoylanilide hy-droxamic acid, Valproic acid, VPA, Trichostatin A
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is consistent with previous reports postulating that an intramolecular hydrogen bond between the amine and carbonyl must be broken to permit successful zinc chelation, and a desolvation penalty is paid for this rearrangement to occur (1, 25-28, 34).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [27]
Citations
Cites
Still being checked.
Cited by
Lauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490706 · Cited by 429
Lee, Y. J., Won, A. J., Lee, J., Jung, J. H., Yoon, S., Lee, B. M., & Kim, H. S. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.5011 · Cited by 123
Li, F., Wu, R., Cui, X., Zha, L., Yu, L., Shi, H., & Xue, B. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.677930 · Cited by 119
Rajak, H., Agarawal, A., Parmar, P., Thakur, B. S., Veerasamy, R., Sharma, P. C., & Kharya, M. D. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.08.022 · Cited by 106
The association between gut butyrate‐producing bacteria and non‐small‐cell lung cancer
Gui, Q., Li, H., Wang, A., Zhao, X., Tan, Z., Chen, L., Xu, K., & Xiao, C. (2020) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23318 · Cited by 105
Metadata
- Authors
- V. Chavan, A., & R. Somani, R.
- Venue
- Mini-Reviews in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-11-01
- Volume
- 10
- Issue
- 13
- Pages
- 1263-1276
- ISSN
- 1389-5575 (ISSN-L)
- OpenAlex
- W2057646700
- Cited by
- 40
- References
- 0
- Citations by year
- 2025: 2 · 2023: 1 · 2022: 1 · 2021: 3 · 2020: 3 · 2018: 3 · 2017: 4 · 2016: 5 · 2015: 1 · 2014: 3 · 2013: 5 · 2012: 4
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Mini-Reviews in Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- histone deacetylase inhibitors, histone deacetylase, histone acetyltransferase, sirtuins, NCoR, SMRT, trichostatin A, vorinostat, valproic acid, butyrate, hydroxamic acids, cancer therapy, anti-inflammatory agents, central nervous system disorders
- MeSH terms
- Acylation, Animals, Central Nervous System Diseases, Histones, Humans, Structure-Activity Relationship, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HDAC Inhibitors-New Generation of Target Specific Treatment. https://app.cochat.ai/papers/10.2174/13895575110091263
- The paper
- V. Chavan, A., & R. Somani, R. (2010). HDAC Inhibitors-New Generation of Target Specific Treatment. Mini-Reviews in Medicinal Chemistry. https://doi.org/10.2174/13895575110091263
